Eva Kassi

Prof. Dr. Eva Kassi

Medical School of Athens, National and Kapodistrian University of Athens, Athens, Greece

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2011 in BMC Medicine
Verified
Journal Article
Open access
PDF file
EKEva Kassi
Eva Kassi
Panagiota PervanidouPanagiota Pervanidou
Panagiota Pervanidou
Gregory KaltsasGregory Kaltsas
Gregory Kaltsas
GCGeorge Chrousos
George Chrousos
Metabolic syndrome (MetS) is a complex disorder defined by a cluster of interconnected factors that increase the risk of cardiovascular atherosclerotic diseases and diabetes mellitus type 2. Currently, several different definitions of MetS exist, causing substantial confusion as to whether they identify the same individuals or represent a surrogate of risk factors. Recently, a number of other factors besides those traditionally used to define MetS that are also linked to the syndrome have been identified. In this review, we critically consider existing definitions and evolving information, and conclude that there is still a need to develop uniform criteria to define MetS, so as to enable comparisons between different studies and to better identify patients at risk. As the application of the MetS model has not been fully validated in children and adolescents as yet, and because of its alarmingly increasing prevalence in this population, we suggest that diagnosis, prevention and treatment in this age group should better focus on established risk factors rather than the diagnosis of MetS.

Verified
Journal Article
Open access
PDF file
NNNarjes Nasiri-Ansari
Narjes Nasiri-Ansari
CNChrysa Nikolopoulou
Chrysa Nikolopoulou
KPKaterina Papoutsi
Katerina Papoutsi
Ioannis KyrouIoannis Kyrou
Ioannis Kyrou
CMChristos S. Mantzoros
Christos S. Mantzoros
EKEva Kassi
Eva Kassi
Aims/hypothesis: SGLT-2 inhibitors (SGLT-2i) have been studied as potential treatments against NAFLD, showing varying beneficial effects. The molecular mechanisms mediating these effects have not been fully clarified. Herein, we investigated the impact of empagliflozin on NAFLD, focusing particularly on ER stress, autophagy and apoptosis. Methods: Five-week old ApoE(-/-) mice were switched from normal to a high-fat diet (HFD). After five weeks, mice were randomly allocated into a control group (HFD + vehicle) and Empa group (HFD + empagliflozin 10 mg/kg/day) for five weeks. At the end of treatment, histomorphometric analysis was performed in liver, mRNA levels of Fasn, Screbp-1, Scd-1, Ppar-γ, Pck-1, Mcp-1, Tnf-α, Il-6, F4/80, Atf4, Elf2α, Chop, Grp78, Grp94, Χbp1, Ire1α, Atf6, mTor, Lc3b, Beclin-1, P62, Bcl-2 and Bax were measured by qRT-PCR, and protein levels of p-EIF2α, EIF2a, CHOP, LC3II, P62, BECLIN-1 and cleaved CASPASE-8 were assessed by immunoblotting. Results: Empagliflozin-treated mice exhibited reduced fasting glucose, total cholesterol and triglyceride serum levels, as well as decreased NAFLD activity score, decreased expression of lipogenic enzymes (Fasn, Screbp-1c and Pck-1) and inflammatory molecules (Mcp-1 and F4/80), compared to the Control group. Empagliflozin significantly decreased the expression of ER stress molecules Grp78, Ire1α, Xbp1, Elf2α, Atf4, Atf6, Chop, P62(Sqstm1) and Grp94; whilst activating autophagy via increased AMPK phosphorylation, decreased mTOR and increased LC3B expression. Finally, empagliflozin increased the Bcl2/Bax ratio and inhibited CASPASE-8 cleavage, reducing liver cell apoptosis. Immunoblotting analysis confirmed the qPCR results. Conclusion: These novel findings indicate that empagliflozin treatment for five weeks attenuates NAFLD progression in ApoE(-/-) mice by promoting autophagy, reducing ER stress and inhibiting hepatic apoptosis.

28 November 2006 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Krystallenia AlexandrakiKrystallenia Alexandraki
Krystallenia Alexandraki
Christina PiperiChristina Piperi
Christina Piperi
CKChristos Kalofoutis
Christos Kalofoutis
JSJaipaul Singh
Jaipaul Singh
AAAntonis Alaveras
Antonis Alaveras
AKAnastasios Kalofoutis
Anastasios Kalofoutis

23 February 2006 in Human Reproduction
Verified
Journal Article
Open access
PDF file
Evanthia Diamanti-KandarakisEvanthia Diamanti-Kandarakis
Evanthia Diamanti-Kandarakis
TPThomas Paterakis
Thomas Paterakis
Krystallenia AlexandrakiKrystallenia Alexandraki
Krystallenia Alexandraki
Christina PiperiChristina Piperi
Christina Piperi
AAAthanasios Aessopos
Athanasios Aessopos
DPDimitrios Panidis
Dimitrios Panidis
BACKGROUND: Women with polycystic ovary syndrome (PCOS) have an increased prevalence of insulin resistance (IR) and related disorders. Elevated serum levels of cellular adhesion molecules (CAMs) reflect low-grade chronic inflammation and have been associated with several insulin-resistant states. The objective of this study is to investigate whether soluble inflammatory markers [soluble intercellular adhesion molecule-1 (sICAM-1), soluble endothelial leukocyte adhesion molecule-1 (sE-selectin), soluble vascular cell adhesion molecule-1 (sVCAM-1) and C-reactive protein (CRP)] are altered in PCOS and to further elucidate the effect of metformin treatment on their levels. METHODS: Two young populations were studied [62 women with PCOS and 45 normal women of similar age, BMI and waist-to-hip ratio (WHR)]. Plasma levels of sICAM-1, sVCAM-1, sE-selectin and high-sensitivity CRP (hsCRP) were measured in both groups. Additionally, the effect of metformin on these molecules was investigated in 22 women with PCOS who accepted to metformin protocol (1700 mg daily for a 6-month period). RESULTS: In the total population studied, plasma levels of hsCRP (mg/l), sICAM-1 (ng/ml) and sE-selectin (ng/ml) were higher in the PCOS group compared with those in controls (hsCRP 1.31 ± 0.22 versus 0.92 ± 0.27, P = 0.014, sICAM-1 301.21 ± 24.80 versus 209.86 ± 17.05, P = 0.025, sE-selectin 57.37 ± 4.08 versus 45.67 ± 4.62, P = 0.045, respectively). sVCAM-1 (ng/ml) did not differ statistically among the two groups (P = 0.896). A significant reduction in hsCRP and sVCAM-1 was achieved after 6 months of metformin administration: PCOS pretreatment hsCRP 1.92 ± 0.60 versus PCOS post-treatment hsCRP 0.52 ± 0.26, P = 0.005; PCOS pretreatment sVCAM-1 668.09 ± 98.38 versus PCOS post-treatment sVCAM-1 365.82 ± 99.77, P = 0.039. CONCLUSION: These findings imply the presence of chronic inflammation in women with PCOS. Metformin decreases the levels of plasma inflammatory indices. Further investigation is required to determine whether these findings may prove to be of clinical significance for PCOS patients.

11 June 2010 in Reviews in Endocrine and Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
Krystallenia AlexandrakiKrystallenia Alexandraki
Krystallenia Alexandraki
AGAshley B. Grossman
Ashley B. Grossman

Verified
Journal Article
Open access
PDF file
Theodoros AndroutsakosTheodoros Androutsakos
Theodoros Androutsakos
NNNarjes Nasiri-Ansari
Narjes Nasiri-Ansari
ABAthanasios-Dimitrios Bakasis
Athanasios-Dimitrios Bakasis
Ioannis KyrouIoannis Kyrou
Ioannis Kyrou
Efstathios P. EfstathopoulosEfstathios P. Efstathopoulos
Efstathios P. Efstathopoulos
EKEva Kassi
Eva Kassi
Non-alcoholic fatty liver disease (NAFLD) is an ‘umbrella’ term, comprising a spectrum ranging from benign, liver steatosis to non-alcoholic steatohepatitis, liver fibrosis and eventually cirrhosis and hepatocellular carcinoma. NAFLD has evolved as a major health problem in recent years. Discovering ways to prevent or delay the progression of NAFLD has become a global focus. Lifestyle modifications remain the cornerstone of NAFLD treatment, even though various pharmaceutical interventions are currently under clinical trial. Among them, sodium-glucose co-transporter type-2 inhibitors (SGLT-2i) are emerging as promising agents. Processes regulated by SGLT-2i, such as endoplasmic reticulum (ER) and oxidative stress, low-grade inflammation, autophagy and apoptosis are all implicated in NAFLD pathogenesis. In this review, we summarize the current understanding of the NAFLD pathophysiology, and specifically focus on the potential impact of SGLT-2i in NAFLD development and progression, providing current evidence from in vitro, animal and human studies. Given this evidence, further mechanistic studies would advance our understanding of the exact mechanisms underlying the pathogenesis of NAFLD and the potential beneficial actions of SGLT-2i in the context of NAFLD treatment.